MX2010008994A - Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. - Google Patents

Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.

Info

Publication number
MX2010008994A
MX2010008994A MX2010008994A MX2010008994A MX2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A
Authority
MX
Mexico
Prior art keywords
combination
paclitaxel
ovarian cancer
treating ovarian
treating
Prior art date
Application number
MX2010008994A
Other languages
English (en)
Inventor
Martine Clozel
Urs Regenass
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40670930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2010008994A publication Critical patent/MX2010008994A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a la combinación de un antagonista del receptor de la endotelina de fórmula (I) con paclitaxel, y, en particular a esta combinación para su uso terapéutico, simultáneamente, por separado o en un período de tiempo, en el tratamiento del cáncer de ovario.
MX2010008994A 2008-02-20 2009-02-19 Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. MX2010008994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008050607 2008-02-20
PCT/IB2009/050677 WO2009104149A1 (en) 2008-02-20 2009-02-19 Combination comprising paclitaxel for treating ovarian cancer

Publications (1)

Publication Number Publication Date
MX2010008994A true MX2010008994A (es) 2010-09-07

Family

ID=40670930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008994A MX2010008994A (es) 2008-02-20 2009-02-19 Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.

Country Status (19)

Country Link
US (2) US8541433B2 (es)
EP (1) EP2254570B1 (es)
JP (1) JP5514123B2 (es)
KR (1) KR20100132489A (es)
CN (1) CN101939001B (es)
AR (1) AR070456A1 (es)
AU (1) AU2009215329B2 (es)
CA (1) CA2714608A1 (es)
CY (1) CY1115071T1 (es)
DK (1) DK2254570T3 (es)
ES (1) ES2446303T3 (es)
HR (1) HRP20140215T1 (es)
MX (1) MX2010008994A (es)
PL (1) PL2254570T3 (es)
PT (1) PT2254570E (es)
RU (1) RU2494736C2 (es)
SI (1) SI2254570T1 (es)
TW (1) TWI441639B (es)
WO (1) WO2009104149A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
MX2010008994A (es) * 2008-02-20 2010-09-07 Actelion Pharmaceuticals Ltd Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
SI3300729T1 (sl) 2008-08-13 2020-02-28 Actelion Pharmaceuticals Ltd. Terapevtski sestavki, ki vsebujejo macitentan
CN102510719B (zh) 2009-08-10 2015-07-22 得克萨斯大学体系董事会 用与细胞毒性化学治疗剂组合的内皮素受体抑制剂治疗脑转移
SG192600A1 (en) 2011-02-04 2013-09-30 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme
CN103819411A (zh) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 一种马西替坦中间体新的制备方法
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
CN100432070C (zh) * 2000-12-18 2008-11-12 埃科特莱茵药品有限公司 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
US20040138121A1 (en) * 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
US20040121971A1 (en) 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010008994A (es) * 2008-02-20 2010-09-07 Actelion Pharmaceuticals Ltd Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
KR20100005486A (ko) * 2008-07-07 2010-01-15 페어차일드코리아반도체 주식회사 스위치 제어 장치 및 이를 포함하는 컨버터

Also Published As

Publication number Publication date
JP5514123B2 (ja) 2014-06-04
HRP20140215T1 (hr) 2014-04-11
PL2254570T3 (pl) 2014-05-30
JP2011512399A (ja) 2011-04-21
CA2714608A1 (en) 2009-08-27
DK2254570T3 (da) 2014-02-03
AR070456A1 (es) 2010-04-07
CN101939001B (zh) 2012-06-20
PT2254570E (pt) 2014-02-17
RU2010138650A (ru) 2012-03-27
KR20100132489A (ko) 2010-12-17
AU2009215329B2 (en) 2014-08-21
US8541433B2 (en) 2013-09-24
AU2009215329A1 (en) 2009-08-27
US20130317048A1 (en) 2013-11-28
SI2254570T1 (sl) 2014-03-31
CN101939001A (zh) 2011-01-05
EP2254570B1 (en) 2013-12-18
RU2494736C2 (ru) 2013-10-10
EP2254570A1 (en) 2010-12-01
US20100311774A1 (en) 2010-12-09
TWI441639B (zh) 2014-06-21
ES2446303T3 (es) 2014-03-07
CY1115071T1 (el) 2016-12-14
WO2009104149A1 (en) 2009-08-27
TW200940062A (en) 2009-10-01

Similar Documents

Publication Publication Date Title
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201171367A1 (ru) Винилиндазолильные соединения
EP2569434A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
UA107782C2 (ru) Антагонисты рецепторов fgf-r4
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
IN2012DN00971A (es)
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
ZA201201984B (en) Treating notch1- antagonist- resistant cancer (s)using notch3 antagonists
PH12015501088A1 (en) Dimeric compounds
MY150600A (en) Use of opioid antagonists for treating urinary retention
EP2340258A4 (en) PROCESS FOR THE SYNTHESIS AND APPLICATIONS OF INHIBITORS OF GHRELIN-O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS AGAINST OBESITAS AND DIABETES
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
HK1141436A1 (en) Axomadol for treating pain from arthritis
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
MX2009007054A (es) Uso terapeutico novedoso para tratar leucemia.
MX2011006532A (es) Compuestos anticancerigenos.
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
FG Grant or registration